Targeting ALK: Precision Medicine Takes on Drug Resistance.

@article{Lin2017TargetingAP,
  title={Targeting ALK: Precision Medicine Takes on Drug Resistance.},
  author={Jessica J Lin and Gregory J Riely and Alice Tsang Shaw},
  journal={Cancer discovery},
  year={2017},
  volume={7 2},
  pages={
          137-155
        }
}
Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-rearranged malignancies, including non-small cell lung cancer. However, the clinical benefit of targeting ALK using tyrosine kinase inhibitors (TKI) is almost universally limited by the emergence of drug resistance. Diverse mechanisms of resistance to ALK TKIs have now been discovered, and these basic mechanisms are informing the development of novel therapeutic strategies to overcome resistance in the clinic. In… CONTINUE READING